Physician profile
Dejun Wang
NPI 1275559288
$1,819.69
in general payments reported to CMS, 2019-2025
16 companies · $19.73 in 2025
The $19.73 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $196 · 2021: $663 · 2022: $616 · 2023: $154 · 2024: $68.29 · 2025: $19.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $566.97 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $321.03 | 2020-2023 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $245.53 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $195.00 | 2019-2022 | |
| Abbvie INC. | $136.91 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $96.02 | 2021-2024 | Linzess |
| Novo Nordisk INC | $53.82 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $47.09 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.43 | 2021-2024 | Xifaxan |
| Gilead Sciences, INC. | $28.16 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.73 | 2025 | Cobenfy |
| Esperion Therapeutics, INC. | $18.45 | 2021 | |
| Eisai INC. | $17.68 | 2020 | |
| Pfizer INC. | $16.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.79 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $9.41 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dejun Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.